This study presents a novel method for cancer immunotherapy utilizing the probiotic Escherichia coli Nissle 1917 (EcN) as an oral delivery system for Glypican-1 (GPC1), a significant tumor-associated antigen in pancreatic cancer treatment. Here, GPC1 is linked to neoplasm.